Q2pharma Programs

Antivirulents vs. Antibiotics

Antivirulents disarm the pathogen of its disease-causing toxins without killing the pathogen, as antibiotics do. Since the survival of the pathogen is not threatened by this treatment there is little if any selective pressure to develop resistance. Indeed, we have not observed any emergence of resistance in 16 daily passages of MRSA.

Superbugs such as MRSA do not always produce toxins, which are usually not required for the proliferation of the organism. Toxins are produced in a disease state. Treatment with an antivirulent blocks the production of toxins and renders the pathogen harmless.

Toxins cause damage to host defense factors. When toxin production is turned off by the antivirulent the immune system remains intact to cure the infection.

Q2-F19 is our first small-molecule antivirulent in the pipeline. It was initially developed against MRSA has been proven efficacious against many Gram-positive pathogens.

Q2-F19 has four beneficial properties

  • Inhibition of toxin formation by the pathogen
  • Inhibition of biofilm formation
  • Potentiation of antibiotic efficacy, even antibiotics to which the pathogen is otherwise resistant
  • Wound healing